Product Cases Studies
At BionFarming GmbH, our unique cyanobacterial platform stands at the forefront of sustainable biotechnological advancements. By leveraging the resilience and efficiency of cyanobacteria, we enable the production of high-value recombinant proteins and peptides with minimal ecological impact. Each case study showcases our commitment to pioneering green processes that not only meet rigorous scientific and industrial standards but also offer a robust alternative to conventional expression systems. Discover how our platform is transforming possibilities in pharmaceuticals, industrial applications, and beyond.
Product Pipeline
AAT
Alpha-1-antitrypsin deficiency is a congenital genetic defect for which there is currently no cure. BionFarming is in the process of developing plant-derived AAT, which is not only a direct substitute, but also replaces a very cost-intensive production with a more cost-effective plant product. Based on the plant-made AAT, BionFarming has started the development of a COVID therapeutic.
Vegan Trastuzumab
Trastuzumab is one of the best-tested and most proven anti-body therapies for breast cancer and other cancers. With the first plant-based biosimilar, BionFarming will create an alternative for all patients who want an animal-free therapy.
BIONFARMING
Enable recycling as in nature
- Closed water-, fertiliser- and energy-cycles
- 100% use of the cultivars, even the roots become usableProductivity increase of over 50% by utilising the roots
- Naturally degradable residues which act as permanent carbon sink
Advancing Cytokine Production with BionFarming – FGF2 and Interferon Alpha 2
At BionFarming, we are continuously pushing the boundaries of cytokine production with our state-of-the-art cyanobacterial platform. Our work in producing cytokines such as Fibroblast Growth Factor 2 (FGF2) and Interferon alpha 2 demonstrates the versatility and efficiency of our system for high-quality, scalable biopharmaceutical manufacturing.
FGF2: Revolutionizing Tissue Regeneration and Wound Healing
Fibroblast Growth Factor 2 (FGF2) plays a critical role in tissue regeneration, wound healing, and angiogenesis. It is an essential therapeutic protein used in regenerative medicine and cosmetic applications. However, traditional production systems like E. coli and mammalian cells face significant challenges, including protein misfolding, costly refolding steps, and complex purification processes.
At BionFarming, we leverage our closed cultivation systems and genetically optimized cyanobacteria to express bioactive FGF2 in its native, fully functional form. By harnessing the natural photosynthetic efficiency of cyanobacteria, we produce FGF2 without the need for complex refolding processes, offering a more cost-effective and scalable solution for the biopharma industry.
Our cyanobacterial platform also ensures minimal contamination risks and consistent production quality, thanks to our sterile CyanoSphere reactors, which are optimized for high-yield cytokine production.
Interferon Alpha 2: A Key Player in Immune Modulation
Interferon alpha 2 is a cornerstone in antiviral therapies and immune modulation, commonly used to treat conditions like hepatitis, certain cancers, and autoimmune disorders. Despite its therapeutic importance, the production of interferon alpha 2 in conventional systems is both costly and resource-intensive.
BionFarming has developed a breakthrough approach by expressing Interferon alpha 2 in our cyanobacteria, eliminating the need for expensive mammalian cell cultures and reducing dependency on complex refolding procedures found in E. coli. The result is a stable, scalable production system capable of delivering high-quality interferon alpha 2 with correct disulfide bond formation and optimal bioactivity.
Our platform’s ability to produce bioactive cytokines like Interferon alpha 2 in a sustainable and efficient manner provides significant advantages in terms of cost and scalability, positioning us as a leader in cytokine production.
Interested in Learning More?
Our advanced work in producing cytokines like FGF2 and Interferon alpha 2 offers a new paradigm for cost-effective, high-quality biopharmaceutical production. To learn more about our platform’s capabilities and how we can help scale your production needs, contact us today for more detailed information and collaborative opportunities.
Breaking Ground in Antimicrobial Peptide Production – LL-37 and Defensins
BionFarming continues to innovate in the field of antimicrobial peptide (AMP) production, focusing on highly bioactive molecules such as LL-37 and other Defensins. These peptides are critical for developing new treatments in the fight against antibiotic-resistant bacteria and are at the forefront of next-generation biopharmaceuticals.
LL-37: The Future of Antimicrobial Therapy
LL-37 is a powerful human antimicrobial peptide (AMP) that plays a critical role in the body’s innate immune defense. It exhibits broad-spectrum activity against bacteria, viruses, and fungi, making it an essential candidate for the development of new antimicrobial therapies.
Traditional production systems for LL-37 face significant challenges. Many systems struggle with protein aggregation, misfolding, and low yields, while others encounter difficulties in expressing cationic, membrane-disruptive peptides like LL-37. This is where BionFarming’s cyanobacterial platform excels.
Our system allows for the stable and scalable production of LL-37 in cyanobacteria, with minimal proteolytic degradation and excellent bioactivity. By using Nutrient Reservoir Technology (NRT) and leveraging our Carbon-Concentrating Mechanism (CCM), we ensure consistent, high-yield production while keeping operational costs low. The result is a sustainable, efficient process that overcomes many of the limitations of traditional expression systems.
Defensins: A New Era in Antimicrobial Peptide Production
In addition to LL-37, our platform is capable of producing a wide range of Defensins, small cationic peptides that play a vital role in the body’s defense against microbial infections. Defensins are increasingly recognized for their potential in treating wound infections, systemic bacterial infections, and even viral infections.
Our cyanobacterial technology provides a breakthrough in the production of Defensins, delivering these peptides in their bioactive form without the need for costly renaturation processes. By optimizing the growth conditions in our closed cultivation systems, we achieve high yields of bioactive Defensins, making them accessible for use in pharmaceutical applications and antimicrobial therapies.
Want to Know More About LL-37 and Defensins?
If you’re interested in learning more about our innovative approach to producing LL-37, Defensins, and other antimicrobial peptides, get in touch with us today. We’d be happy to discuss how our platform can meet your production needs and offer a sustainable, cost-effective solution for your next-generation therapeutics.
BionFarming – Harnessing the Power of Cyanobacteria for Sustainable, Scalable Biopharmaceutical Solutions